新建医院ICU临床分离菌的分布及耐药变迁

doi:10.6040/j.issn.1671-7554.0.2019.1088

摘要/Abstract

摘要： 目的研究新建医院ICU自建院以来的病原菌分布情况及耐药性变化,为医院感控管理和临床感染防治工作提供依据。方法回顾性分析2014年1月至2018年12月ICU临床标本培养阳性的菌株分布和耐药情况。采用法国梅里埃公司的全自动微生物鉴定仪进行细菌鉴定,主要应用相对数和卡方检验进行统计学分析。结果 1 784株病原菌中,革兰阴性菌占68.27%,以鲍曼不动杆菌、铜绿假单胞菌、大肠埃希菌和肺炎克雷伯菌居多,标本主要来源为痰液(62.89%)和尿液(11.49%);革兰阳性菌占21.13%,主要包括金黄色葡萄球菌、屎肠球菌,标本主要来源为血液(30.77%)和尿液(23.08%)。同种细菌中,多重耐药鲍曼不动杆菌(MDR-AB)在建院第二年的年检出率升至93.75%,泛耐药鲍曼不动杆菌(XDR-AB)在2015年4月份开始流行;产ESBLs大肠埃希菌(ESBLs-EC)、耐碳青霉烯铜绿假单胞菌(CR-PA)、耐甲氧西林金黄色葡萄球菌(MRSA)和耐甲氧西林凝固酶阴性葡萄球菌(MRCNS)的平均检出率分别为68.31%、53.48%、60.55%和86.87%。在2014年检出耐万古霉素的屎肠球菌1株。结论新建医院ICU需警惕和预防鲍曼不动杆菌的环境定植和感染暴发。ICU分离病原菌中非发酵革兰阴性杆菌、葡萄球菌、肠球菌的耐药形势严峻,需加强对MDR-AB、CR-PA、MRSA、MRCNS、ESBLs-EC的监测,积极预防下呼吸道、尿路感染及导管相关血流感染,根据耐药流行病学合理选用抗菌药物。

关键词: 新建医院, 重症医学科, 临床分离菌, 耐药变迁

Abstract: Objective To clarify the distribution and drug resistance change of clinical isolates in ICU of a new hospital, and to provide evidence for clinical infection prevention and management. Methods The distribution and drug sensitivity of positive strains were retrospectively analyzed from January 2014 to December 2018 in ICU. Bacteria identification was carried out by the full-automatic microbial identification instrument of French Merrier, and the relative numbers and chi-square test were mainly used for statistical analysis. Results 68.27% of 1784 strains were Gram-negative bacteria mainly from sputum(62.89%)and urine(11.49%), and most of them were Acinetobacter baumannii, Pseudomonas aeruginosa, Escherichia coli and Klebsiella pneumoniae. 21.13% of 1784 strains were Gram-positive bacteria mainly from blood(30.77%)and urine(23.08%), and most of them were Staphylococcus aureus and Enterococcus faecalis. Among the same species of bacteria, the detection rate of multidrug-resistant Acinetobacter baumannii(MDR-AB)was 93.75% in the second year. Extensively drug resistant Acinetobacter baumannii(XDR-AB)had been preva- 山东大学学报 (医学版)58卷2期 -孙艳婷,等. 新建医院ICU临床分离菌的分布及耐药变迁 \=-lent in April 2015. The average detection rate of ESBLs-producing Escherichia coli(ESBLs-EC), carbapenem-resistant Pseudomonas aeruginosa(CR-PA), methicillin-resistant Staphylococcus aureus(MRSA)and methicillin-resistant Coagulase-negative staphylococcus(MRCNS)were 68.31%, 53.48%, 60.55% and 86.87%, respectively. One strain of vancomycin-resistant Enterococcus faecalis was detected in 2014. Conclusion The new ICU should strengthen prevention of Acinetobacter baumannii colonization and epidemics. The drug resistance of isolates, especially non-fermenting Gram-negative bacilli, staphylococcus and enterococci, is significant in ICU. It is necessary to monitor drug resistance of MDR-AB, CR-PA, MRSA, MRCNS and ESBLs-EC, prevent nosocomial infection, and select rational antibiotics according to the prevalence of drug resistance.

Key words: New hospital, Intensive Care Unit, Clinical isolates, Resistance change

中图分类号:

R378

孙艳婷,吴大玮,王晓斐,徐建,王睿. 新建医院ICU临床分离菌的分布及耐药变迁[J]. 山东大学学报 (医学版), 2020, 58(2): 64-71.

SUN Yanting, WU Dawei, WANG Xiaofei, XU Jian, WANG Rui. Distribution and drug resistance change of clinical isolates in ICU of a new hospital[J]. Journal of Shandong University (Health Sciences), 2020, 58(2): 64-71.

参考文献 38

[1]	刘延一, 杨俊华, 叶丹. 慢性阻塞性肺病急性加重患者呼吸道多重耐药菌感染危险因素分析[J]. 临床肺科杂志, 2019, 24(4): 661-664. LIU Yanyi, YANG Junhua, YE Dan. Analysis of risk factors for lower respiratory tract infections caused by multi-drug resistant bacterial in AECOPD patients[J]. Journal of Clinical Pulmonary Medicine, 2019, 24(4): 661-664.
[2]	莫元春, 李沃田, 杨文, 等.危急值管理在多重耐药菌感染控制中的应用[J]. 中华医院感染学杂志, 2019, 29(10): 1575-1578. MO Yuanchun, LI Wotian, YANG Wen, et al. Application of critical value management in control of multidrug-resistant orgnisms infection[J]. Chin J Nosocomiol Vol, 2019, 29(10):1575-1578.
[3]	李占结, 刘波, 李惠芬, 等. ICU多重耐药菌感染分布与来源研究[J]. 中华医院感染学杂志, 2019, 29(8): 1166-1171. LI Zhanjie, LIU Bo, LI Huifen, et al. Study on distribution and source of multi-duyg resistant bacteria infection in ICUs[J]. Chin J Nosocomiol Vol, 2019, 29(8): 1166-1171.
[4]	余跃天, 马朋林. 重症监护病房多重耐药菌防控:指南与实践[J]. 中华医学杂志, 2019, 99(25): 1945-1948. YU Yuetian, MA Penglin. Prevention and control of multidrug-resistant organisms: guidelines vs practice[J]. Natl Med J China, 2019, 99(25): 1945-1948.
[5]	Mody L. Translational models of infection prevention and control: lessons from studying high risk aging populations[J]. Curr Opin Infect Dis, 2018, 31(4): 359-367.
[6]	Woodworth KR, Walters MS, Weiner LM, et al. Vital signs containment of novel multidrug-resistant organisms and resistance mechanisms—United States, 2006-2017[J]. MMWR Morb Mortal Wkly Rep, 2018, 67(13): 396-401.
[7]	Gopalsamy SN, Woodworth MH, Wang T, et al. The use of microbiome restoration therapeutics to eliminate intestinal colonization with multidrug-resistant organisms[J]. Am J Med Sci, 2018, 356(5): 433-440.
[8]	徐雅萍,霍瑞,闫中强,等.MDR,XDR,PDR细菌国际专家关于获得性耐药暂行定义的提案[J].中华医院感染学杂志,2017,27(1): 231-240.
[9]	姚琳,王书会,邓钰,等.综合性ICU患者医院感染情况及危险因素监测分析[J].山东大学学报(医学版),2009,47(10):110-113. YAO Lin, WANG Shuhui, DENG Yu, et al. Surveillance and analysis of nosocomial infections and risk factors in integrated ICU[J]. Journal of Shandong University(Health Sciences), 2009, 47(10): 110-113.
[10]	郭龙飞,胡逢静,蔡玲,等.重症医学科医院感染现状及其风险评估研究进展[J].中华医院感染学杂志,2019,29(8):1263-1266. GUO Longfei, HU Fengjing, CAI Ling, et al. Current status of nosocomial infection in intensive care unit and research progress of its risk assessment[J]. Chin J Nosocomiol Vol, 2019, 29(8): 1263-1266.
[11]	张莉莉, 左改珍. 重症监护室医院感染目标性监测分析与对策[J]. 中国感染控制杂志, 2008, 7(2): 103-105. ZHANG Lili, ZUO Gaizhen. Study on objective surveillance and strategies of nosocomial infection in patients in intensive care unit[J]. Chin Infect Control, 2008, 7(2):103-105.
[12]	Simsek S, Yurtseven N, Gercekogalu H. Ventilator-associated pneumonias in a cardiothoracic surgery center postoperative intensive care unit[J]. Hosp Infect, 2001, 47(4): 321-324.
[13]	朱熠,李辉,庄建文,等.某综合医院重症监护病房病原菌分布及耐药性分析[J].中国消毒学杂志,2018,35(6):420-427. ZHU Yi, LI Hui, ZHUANG Jianwen, et al. Analysis on distribution and drug resistance of pathogenic bacteria in intensive care unit of a general hospital[J]. Chin J Disinfection, 2018, 35(6): 420-427.
[14]	王蕾,杨紫旋,康海全,等.某教学医院重症监护病房与普通病房细菌分布及耐药性比较分析[J].疾病监测,2018,33(9): 762-765. WANG Lei, YANG Zixuan, KANG Haiquan, et al. Analysis of distribution and drug resistance of bacteria in ICU and general wards of a teaching hospital[J]. Dis Surveill, 2018, 33(9): 762-765.
[15]	万瑛.我院ICU病原菌分布及耐药性分析[J].齐齐哈尔医学院学报,2018,39(6):669-671.
[16]	宋世平, 李艳, 陈建魁, 等. MICU病原菌分布及泛耐药菌感染危险因素分析[J]. 中华医院感染学杂志, 2012, 22(17): 3715-3735. SONG Shiping, LI Yan, CHEN Jiankui, et al. Distribution of pathogens in MICU and risk factors for pandrug-resistant bacteria infections[J]. Chin J Nosocomiol Vol, 2012, 22(17): 3715-3735.
[17]	谢多希, 吕百勤, 王淑珠, 等. ICU常用抗生素应用与病原菌变迁的相关性探讨[J]. 中国微生态学杂志, 2007, 19(6): 564-565.
[18]	徐敏洁. 抗生素轮换在新生儿重症监护病房控制细菌耐药中的应用[J]. 中国妇幼保健, 2015(23): 68-70. doi: 10.3969/j.issn.1003-515X.2011.10.016.
[19]	郭仲辉, 黎毓光, 卓超. 抗生素压力下铜绿假单胞菌耐药机制变化的动态研究[J].中国抗生素杂志, 2010, 35(9): 715-720. GUO Zhonghui, LI Yuguang, ZHUO Chao. Change of antimicrobial resistance in Pseudomonas aeruginosa under the antibiotic pressure[J]. Chin J Antibio, 2010, 35(9): 715-720.
[20]	Linares JF, Gustafsson I, Baquero F, et al. Antibiotics as intermicrobial signaling agents instead of weapons[J]. Proc Natl Acad Sci U S A, 2006, 103(51): 19484-19489.
[21]	Bagge N, Schuster M, Hentzer M, et al. Pseudomonas aeruginosa biofilms exposed to imipenem exhibit changes in global gene expression and β-lactamase and alginate production[J]. Antimicrob Agents Chemother, 2004, 48(4): 1175-1187.
[22]	Day T, Huijben S, Read AF. Is selection relevant in the evolutionary emergence of drug resistance? [J]. Trends Microbiol, 2015, 23(3): 126-133.
[23]	肖淑珍, 徐桂婷, 方洁, 等. 鲍曼不动杆菌耐药性与抗菌药物使用情况的相关性分析[J]. 中国感染与化疗杂志, 2013, 13(6): 446-449. XIAO Shuzhen, XU Guiting, FANG Jie, et al. Relationship between antibiotic use and antimicrobial resistance in Acinetobacter baumannii[J]. Chin J Infect Chemother, 2013, 13(6): 446-449.
[24]	Leclercq R, Derlot E, Duval J, et al. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium [J]. N Engl J Med, 1988, 319(3): 157-161.
[25]	Mendes RE, Flamm RK, Hogan PA, et al. Summary of linezolid activity and resistance mechanisms detected during the 2012 LEADER surveillance program for the United States [J]. Antimicrob Agents Chemother, 2014, 58(2): 1243-1247.
[26]	Weist K, H(¨overo)gberg LD. ECDC publishes 2015 surveillance data on antimicrobial resistance and antimicrobial consumption in Europe[J]. Euro Surveill, 2016, 21(46): pii: 30399. doi: 10.2807/1560-7917.ES.2016.21.46.30399.
[27]	国家卫生计生委合理用药专家委员会,全国细菌耐药监测网.2015年全国细菌耐药监测报告[J].中国执业药师,2016,13(3):3-8.
[28]	伍国强,梁海云,李朝阳,等.急诊住院病房多重耐药鲍曼不动杆菌医院内感染暴发的原因调查及控制对策[J].现代医药卫生,2014,30(9):1322-1324. WU Guoqiang, LIANG Haiyun, LI Zhaoyang, et al. Investigation on outbreak of nosocomial infection of multi-drug resistant acinetobacter baumannii in the wards of emergency department and control countermeasures[J]. J Mod Med Health, 2014, 30(9): 1322-1324.
[29]	王莉,周凤萍.ICU多重耐药鲍曼不动杆菌医院感染暴发流行病学调查[J].中国感染控制杂志,2013,12(2):113-116. WANG Li, ZHOU Fengping. Survey on an outbreak of healthcare-associated infection with multidrug-resistance Acinetobacter baumannii in an intensive care unit[J]. Chin J Infect Control Vol, 2013, 12(2): 113-116.
[30]	王玲,杨连松,王清华,等.耐碳青霉烯类鲍氏不动杆菌医院获得性肺炎危险因素分析[J].中华医院感染学杂志,2011,21(14):2954-2956. WANG Ling, YANG Liansong, WANG Qinghua, et al. Risk factors of hospital-acquired pneumonia caused by carbapenem-resistant acinetobacter baumannii[J]. Chin J Nosocomiol Vol, 2011, 21(14): 2954-2956.
[31]	Djeribi R, Bouchloukh W, Jouenne T, et al. Characterization of bacterial biofilms formed on urinary catheters[J]. Am J Infect Control, 2012, 40(9): 854-859.
[32]	Gordon NC, Wareham DW. Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance[J]. Int J Agents, 2010, 35(3): 219-226.
[33]	Antunes LC, Visca P, Towner KJ. Acinetobacter baumannii: evolution of a global pathogen[J]. Pathog Dis, 2014, 71(3): 292-301.
[34]	Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii[J]. Nat Rev Microbiol, 2007, 5(12): 939-951.
[35]	McConnell MJ, Actis L, Pachón J. Acinetobacter baumannii: human infections, factors contributing to pathogenesis and animal models[J]. FEMS Microbiol Rev, 2013, 37(2): 130-155.
[36]	谢少清,左改珍,范恒梅,等.重症监护病房鲍氏不动杆菌医院感染暴发及控制[J].中华医院感染学杂志,2010,20(12):1661-1663. XIE Shaoqing, ZUO Gaizhen, FAN Hengmei, et al. Outbreak and control of hospital infection of Acinetobacter baumannii in ICU[J]. Chin J Nosocomiol, 2010, 20(12): 1661-1663.
[37]	高鸿章.EICU和ICU患者鲍曼不动杆菌定植、感染发生率及治疗和转归情况调查研究[J].中国现代药物应用,2018,12(7):74-75.
[38]	Gramatniece A, Silamikelis I, Zahare I, et al. Control of Acinetobacter baumannii outbreak in the neonatal intensive care unit in Latvia: whole-genome sequencing powered investigation and closure of the ward[J]. Antimicrob Resist In, 2019, 8(1): 1-8.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed